18 August 2025
Swissmedic: Benchmarking Study 2024
Swissmedic has published its benchmarking study for 2024, which was made in cooperation with the Swiss pharmaceutical industry associations (ASSGP, Intergenerika, Interpharma, scienceindustries and vips). The study analyses the times required to authorise human medicinal products in Switzerland and compares them with the equivalent times from the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). The study showed that Swissmedic generates stable throughput for new active substances, meaning it is catching up with EMA in international comparisons. However, the FDA remains significantly faster with over 40% shorter throughput times.
For more information, see here.
More News
-
-
Swissmedic: New strategic Approach to minimizing Animal Testing in the Development of Medicinal Products
-
Swissmedic: The new Pharmacopoea Helvetica 13
-
European Medicines Agency: New oral GLP-1 Medicine for Weight Management and Type 2 Diabetes
-
FOPH: Capital Income of Health Insurers for Premium Reduction – current voluntary System deemed sufficient
-
Decision C-6534/2024 of 13 October 2026
-
Swissmedic: Haemovigilance Annual Report 2025
-
Swissmedic: GMP Compliance by foreign Manufacturers - Simplifications for Industry and Clarification of unresolved Issues
-
European Medicines Agency: Clinical Trial Applications Advice Pilot becomes permanent
-
European Medicines Agency: Highlights of the September 2026 Management Board meeting